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Background: Diabetes is probably responsible for worsening of metabolic syndrome (MetS)components. The aim
of the present study was to compare the components of MetS between premenopausal and postmenopausal
women with type 2 diabetes (T2DM).
Method: In this cross sectional study, we studied 639 women with T2DM that were divided in pre-menopausal
(n = 221) and post-menopausal (n = 418) group. They were selected from participants of a diabetes clinic and
assessed for MetS and its components. All MetS components were evaluated to follow age and duration of diabetes
adjusted according to the ATP III criteria.
Results: The mean ages of pre-menopausal and post-menopausal were 43.33 ± 0.47 and 60.35 ± 0.38 years,
respectively. MetS was defined for 88.3% of total subjects (87.5% and 87.7% in pre-menopausal and post-menopausal
women with T2DM respectively). Systolic blood pressure (SBP) and waist circumference (WC) were significantly higher
in post-menopausal women with T2DM in comparison with pre-menopausal ones. There were no significant
differences in triglyceride (T.G) level, diastolic blood pressure (DBP) and high density lipoprotein cholesterol
(HDL-C) between the two groups. Myocardial infarction (MI) occurred in 1% total subjects (1.3% and 1.8%) in
pre-menopausal and post-menopausal women with T2DM, respectively (p = 0.21).
Conclusion: Worsening of MetS and its components except for SBP and waist circumference has been shown
in pre-menopausal women with T2DM similar to post-menopausal ones. The observed differences may be
explained by increasing age. With respect to increasing of myocardial infarction in premenopausal subjects, we
suggest that diabetes can abolish the protective effects of premenopausal status for MetS and MI.
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Metabolic syndrome (MetS) is a cluster of characteristics
related to insulin resistance that increase the risk of car-
diovascular disease (CVD) and type II diabetes mellitus
(T2DM) [1]. Global prevalence of MetS is predicted to
increase in the global population over coming years [2].
One study reported a MetS prevalence of 58% in the
general population of Iran [1]. It is possible that an in-
creasing global prevalence of MetS will contribute to an
increase in the number of cases of diabetes worldwide* Correspondence: nakhjavanim@tums.ac.ir
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article, unless otherwise stated.[3]. Furthermore, post-menopausal status presents with
an increase in MetS characteristics and CVD, which are
principally caused by the loss of female sex hormones
[4]. Some studies have reported that menopausal status
is an independent predictor of MetS among women
[1,5]. However, no studies have assessed MetS and its
components in a diabetic population of women. There is
lack of data on the relationship between MetS and its
components and menopausal status in diabetic women.
The aim of the present study was to assess and compare
MetS and its components in pre-menopausal and post-
menopausal women with T2DM.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this







(n = 221) (n = 418)
Age (years) 43.33 ± 0.47 60.35 ± 0.38 < 0.001
Duration of diabetes (years) 6.21 ± 0.38 9.17 ± 0.35 < 0.001
Weight (Kg) 73.39 ± 0.95 71.84 ± 0.62 0.15
BMI (Kg/m2) 29.02 ± 0.35 28.75 ± 0.23 0.51
Uric acid (mg/dl) 4.34 ± 0.19 5.18 ± 0.22 < 0.05
Urea (mg/dl) 27.35 ± 0.95 31.06 ± 0.81 < 0.01
Creatinine (mg/dl) 0.85 ± 0.01 1.01 ± 0.03 < 0.005
HbA1C (%) 8.41 ± 0.18 8.40 ± 0.10 0.94
Post-prandial glucose (mg/dl) 265.79 ± 9.57 251.10 ± 6.80 0.21
Total Cholesterol (mg/dl) 185.76 ± 3.39 190.56 ± 2.63 0.27
LDL (mg/dl) 106.36 ± 3.83 103.43 ± 2.27 0.48
Triglycerides/HDL 4.23 ± 0.28 4.37 ± 0.21 0.71
Non-HDL cholesterol/HDL 3.19 ± 0.11 3.18 ± 0.08 0.91
AST (mg/dl) 22.04 ± 1.28 23.50 ± 1.43 0.52
ALT (mg/dl) 22.49 ± 1.36 24.69 ± 1.19 0.26
Albuminuria (mg/24 h) 8.17 ± 0.13 6.81 ± 0.07 0.21















BMI, body mass index; HbA1C, hemoglobin A1C; LDL, low density lipoprotein
cholesterol; HDL, high density lipoprotein cholesterol; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; eGFR, estimated glomerular
filtration rate; ACEI, angiotensin converting enzyme inhibitor; ARB, aldosterone
receptor blocker; CCB, calcium channel blocker.Note: topographic mean was
represented for albuminuria.
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We performed a clinical, cross-sectional study. The study
population consisted of 639 participants, including 221 pre-
menopausal women with T2DM and 418 post-menopausal
women with T2DM. Patients were recruited from the dia-
betes clinic of Vali-Asr Hospital, which is affiliated with
Tehran University of Medical Sciences.
We defined menopausal status according to the defin-
ition of the Reproductive Aging Workshop (2011) [6].
Pregnant women, patients with a mental or physical dis-
ability and women who had used hormone replacement
therapy or oral contraceptive pills within the previous
six months were excluded.
MetS was defined according to National Cholesterol
Education Adult Treatment Panel III (NCEP ATP III)
criteria [7]. As detailed in the NCEP ATP III report,
participants having three or more of five following cri-
teria were defined as having the metabolic syndrome:
high blood pressure (>130/>85 mmHg) or known
hypertensive patients, elevated fasting blood glucose
(FBS >100 mg/dl or >5.55 mmol/l) or known diabetic pa-
tients, hypertriglyceridemia (>150 mg/dl or >1.65 mmol/
l), high density lipoprotein (HDL)-cholesterol: (women <
50 mg/dl or <1.30 mmol/l), and abdominal obesity, as
measured by a waist circumference of ≥88 cm for women.
The research was carried out according to the principles
of the declaration of Helsinki. The ethics committee of the
Tehran University of Medical Science approved the study
protocol. In the diabetes clinic, interviews were under-
taken by physicians in order to obtain information about
the patients’ history. Anthropometric measurements were
conducted by well-trained examiners. Waist circumfer-
ence (WC) was measured at the midpoint between the last
rib and the iliac crest, directly on the skin. Weight was
measured by a calibrated balance beam scale. BMI (kg/
m2) was calculated according to the Quetelet formula.
Blood pressure was measured with a standard calibrated
mercury sphygmomanometer, applied to the right arm
after 15 minutes of rest in the sitting position. In pre-
menopausal subjects, 80.9% were being treated with
one oral hypoglycemic agent and 19.1% received insulin
therapy. In post-menopausal women, 75.4% received
oral hypoglycemic agents and the other 24.6% received
insulin as a glucose-lowering drug (Table 1). Enzymatic
methods were used for the measurement of total chol-
esterol and triglycerides. Total cholesterol and high-
density lipoprotein (HDL) cholesterol were measured
by cholesterol oxidase phenol aminoantipyrine assays.
IFCC methods were used to estimate human haemoglo-
bin A1C. MetS was defined according to criteria from
the NCEP ATP III [7], which defines MetS as the pres-
ence of at least three of the following: abdominal obes-
ity as determined by an elevated WC of greater than
88 cm for women; a HDL cholesterol level lower than50 mg/dl; triglyceride levels of 150 mg/dl or higher; sys-
tolic blood pressure of 130 mmHg or higher and dia-
stolic blood pressure of 85 mmHg or higher or known
hypertensive patients; diabetes mellitus. We also used
IDF criteria with a recently defined local Iranian cut-off
point for WC (≥85.5) according to Esteghamati et al. as
an alternative measurement [8].
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All data were analysed separately for pre-menopausal
and post-menopausal groups. For continuous variables,
mean ± SD was calculated. Data analysis was performed
with the statistical package for the social sciences pro-
gram (SPSS for windows, version 17; Chicago, IL). Stu-
dent’s t-test and analysis of variance considering age
and duration of diabetes as covariates were used to
compare the variables between the two groups. Adjust-
ments were made for all independent variables. Odds
ratios with 95% CI were calculated by binary logistic re-
gression analysis for factors affecting MetS. All analyses
were two-tailed and a P-value of less than 0.05 was con-
sidered statistically significant.Results
MetS was defined for 88.3% of total subjects (87.5%
and 87.7% in pre-menopausal and post-menopausal
women with T2DM, respectively) (P = 0.34). Table 1
shows baseline characteristics of the study population.
The participants were divided in two groups: 221
(34.6%) pre-menopausal women with T2DM and mean
age of 43.33 ± 0.47 and 418 (65.4%) post-menopausal
women with T2DM and mean age of 60.35 ± 0.38.
Comparisons of the MetS components in pre- and
post-menopausal groups are presented in Table 2.
There were significant differences in WC (P <0.01) and
systolic HTN (P <0.001) between the two groups.
The association of MetS components with meno-
pausal status in women with T2DM is shown in Table 3.
In a multivariate logistic regression model with meno-
pausal status as the outcome and MetS components as
independent variables, there were significant differences
in systolic HTN (odds ratio: 1.83, P <0.001) between the
two groups (model 2). In model 3, menopausal status was
defined as the outcome and metabolic syndrome compo-
nents, duration of diabetes, BMI and haemoglobin A1C
were defined as independent variables. SBP and WC dif-
fered significantly between the two groups.Table 2 Metabolic syndrome components in pre- and
post-menopause women with type 2 diabetes
Pre-menopause Post-menopause P-value
(n = 221) (n = 418)
Waist (cm) 93.29 ± 0.9 96.17 ± 0.59 < 0.01
SBP (mmHg) 124.46 ± 1.42 131.42 ± 1.09 < 0.001
DBP (mmHg) 77.96 ± 0.88 78.41 ± 0.71 0.54
Triglycerides (mg/dl) 185.54 ± 9.07 190.42 ± 6.82 0.67
HDL (mg/dl) 47.08 ± 1.50 47.04 ± 0.81 0.98
FBS (mg/dl) 185.91 ± 5.24 183.65 ± 3.80 0.72
SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density
lipoprotein; FBS, fasting blood sugar.The components of MetS, according to the ATP III
Index, in pre-menopausal and post-menopausal women
with T2DM are shown in Figure 1.
Discussion
In the present study, the differences between the compo-
nents of MetS in post-menopausal women compared with
pre-menopausal women were questioned, as T2DM was
the underlying condition. There was no significant differ-
ence in MetS prevalence in pre-menopausal and post-
menopausal women with T2DM. In the present study,
WC and systolic blood pressure differed significantly be-
tween pre-menopausal and post-menopausal women with
T2DM. Diastolic blood pressure, triglycerides, HDL-C
and FBS did not differ between the two groups.
The frequency of MetS increases from the beginning
of the menopausal transition to post menopause and
the defined components of MetS are more frequent in
non-diabetic, post-menopausal women compared to pre-
menopausal women [1,9]. Ainy et al. [1] reported that the
prevalence of MetS is 53% in pre-menopausal women and
69% in post-menopausal women [1]. This calls into ques-
tion how the presence of T2DM reduces the differences
observed between pre- and post-menopausal women.
Diabetes is an inflammatory state, characterised by
increased plasma levels of reactive oxygen species, lipid
per oxidation products, CRP, ferritin and other reactive
compounds, which all increase with inflammatory process
[10,11]. Furthermore, it has been shown that women with
T2DM secrete higher levels of inflammatory factors such
as Interleukin 6 (IL-6) and thus have a greater stress re-
sponse than men [12].
In this study, HDL-C level did not differ in pre-
menopausal compared with post-menopausal status in dia-
betic women. It has been proposed that in patients with
T2DM, HDL is less effective at inhibiting oxidation and
cholesterol efflux stimulation from macrophage [13,14].
In the presence of systemic inflammatory condition the
atheroprotective effect of apolipoproteins and lipids
may be lost; so that, for instance, high HDL-C plasma
levels may be proatherogenic rather than protective
[15]. Despite the loss of oestrogen during menopause,
some studies have reported a gradual increase in HDL-
C in women with T2DM [16]. In fact, menopause itself
is not associated with a reduction in HDL-C levels, and
there is a possibility that findings of low HDL-C levels
in post-menopausal women in most previous reports
may be due to weight gain, lack of physical activity and
associated metabolic disease such as T2DM in older
women [17].
In the present study, WC differed between pre-
menopausal and post-menopausal groups. Abdominal
obesity is one of the main clinical features of MetS in
post-menopausal patients with T2DM [18]. Weight
Table 3 Association of metabolic syndrome components with menopause status in women with type 2 diabetes
Model 1 Model 2 Model3
Waist OR 1.26 (1.06 – 1.50) 1.13 (0.88 – 1.45) 1.56 (1.00 – 2.29)
p-value p <0.01 p = 0.32 p = 0.05
SBP OR 1.39 (1.17 – 1.66) 1.83 (1.25 – 2.68) 1.63 (1.03 – 2.59)
p-value p <0.001 p <0.005 p <0.05
DBP OR 1.05 (0.89 – 1.24) 0.70 (0.47 – 1.05) 0.88 (0.54 – 1.41)
p-value p = 0.54 p = 0.09 p = 0.60
Triglycerides OR 1.04 (0.85 – 1.28) 1.02 (0.78 – 1.34) 0.97 (0.71 – 1.33)
p-value p = 0.67 p = 0.83 p = 0.88
HDL OR 0.99 (0.80 – 1.23) 0.98 (0.76 – 1.26) 1.03 (0.75 – 1.42)
p-value p = 0.98 p = 0.91 0.82
FBS OR 0.96 (0.80 – 1.15) 0.93 (0.73 – 1.19) 0.90 (0.64 – 1.25)
p-value p = 0.725 p = 0.61 p = 0.54
SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high density lipoprotein; FBS, fasting blood sugar, OR, odds ratio.
Model 1: Univariate logistic regression model with menopause status as outcome variable.
Model 2: Multivariate logistic regression model with menopause status as outcome and metabolic syndrome components as independent variables.
Model 3: Multivariate logistic regression model with menopause status as outcome and metabolic syndrome components and duration of diabetes, body mass
index and hemoglobin A1C as independent variables.
Note: Odds ratios were calculated for 1 standard deviation change in independent variable.
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changes associated with the menopause [19]. Although
increased visceral adiposity during menopausal transi-
tion is associated with increasing insulin resistance, ele-
vated free fatty acid levels, as well as decreased adiponectin
levels, have also been observed [2]. Studies have concluded
that the average steady weight gain of about 0.5 kg annually
observed in post-menopausal women, is caused by age ra-
ther than the menopause itself [19]. This suggests that in-
creased WC in post-menopausal women may be caused by
increasing age.
In the current study, post-menopausal women had higher
systolic blood pressure compared to pre-menopausal
women with T2DM (P <0.005) but there was no significant
difference in diastolic blood pressure between the groups.







Figure 1 The Met S Components according to ATP III Index in premeno
blood suger; WC: Waist circumference; HDL: High density lipoprotein; TG: Trigsystolic blood pressure increases progressively with age,
whereas diastolic blood pressure rises until 60 years of age,
after which it starts to decline [20].
A twofold increase in CVD risk has been reported in
post-menopausal women compared to pre-menopausal
women [2]. However, in patients with diabetes, pre-
menopausal women lose some protective factors ob-
served in their healthy counterparts. A worsening of
the plasma lipid profile may contribute to the loss of
CVD protection seen in diabetic women [21,22]. Also,
the pre-menopausal advantage in the clearance of dietary
lipids in healthy subjects is not seen in pre-menopausal
women with T2DM [21]. Another important finding is
that in pre-menopausal women with T2DM, reduced cor-
onary vasodilator function and impaired response of re-
sistance vessels to increased sympathetic stimulation is150 200
postmenopause
premenopause
pausand post menopausal women with type II diabetes. FBS: Fasting
lycerid; SBP: Systolic blood pressure; DBP: Diastolic blood pressure.
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diabetic post-menopausal women [23]. Besides the differ-
ent mechanisms associated with diabetes, Aviles-Santa
et al. [24] showed that risk of CVD in pre-menopausal
women with T2DM who have multiple features of MetS is
underestimated according to the Framingham scoring
system.
Furthermore, diabetes can attenuate protective effects
of oestrogen in premenopausal status [18]. Studies show
that oestrogen deficiency appears to be associated with
an increased risk of cardiovascular events [18,25]. In
non-diabetic women, one of the beneficial effects of
oestrogen in terms of the prevention of CVD and its risk
factors is the increase in the basal release of nitric oxide
(NO) from endothelial cells [15]. One of the possible ex-
planations for the effects of the loss of oestrogen on vas-
cular protection in diabetes is that oestrogen fails to
affect basal NO release and alter vasodilation [15,26]. As
a result, hormone replacement therapy (HRT) has dem-
onstrated to cause both favourable changes in lipid pro-
files and the reduction of coronary heart disease in
women with T2DM [27-30]. Greater benefits from HRT
are expected if glucose metabolism has previously been
normalised [22]. Moreover, the diabetic setting has been
strongly associated with lower sex hormone binding
globulin (SHBG) levels [29]. Lower SHBG level is con-
sidered to be detrimental to vasculature in women [29].
The main limitation of the present study was the
cross-sectional study design used, which precludes the
determination of the direction of causality. However, this
is the first study to compare MetS in pre- and post-
menopausal diabetic women.
In Conclusion, MetS must be evaluated in diabetic pa-
tients regardless of the time of menopausal transition
[24]. In patients with diabetes, pre-menopausal women
lose some protective factors observed in their healthy
counterparts. In the present study, the pre-menopausal
group suffered from the same incidence of MI as the
post-menopausal group. Primary prevention through
changes in lifestyle and diet and secondary prevention
through early detection and good control of diabetes are
necessary for the prevention of MetS and cardiovascular
disease in Iranian women with T2DM, regardless of their
menopausal status.
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